SCM
CSTL icon

Sterling Capital Management’s Castle Biosciences CSTL Stock Holding History

Sterling Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Sell
603
-368
-38% -$8.2K ﹤0.01% 2042
2026
Q1 		$23.8K Sell
971
-666
-41% -$21.8K ﹤0.01% 1955
2025
Q4 		$63.7K Sell
1,637
-323
-16% -$10.4K ﹤0.01% 1711
2025
Q3 		$44.6K Buy
1,960
+1,193
+156% +$24.2K ﹤0.01% 1790
2025
Q2 		$15.7K Buy
767
+451
+143% +$8.35K ﹤0.01% 1885
2025
Q1 		$6.33K Sell
316
-256
-45% -$6.34K ﹤0.01% 2040
2024
Q4 		$15.2K Buy
572
+500
+694% +$15.2K ﹤0.01% 1970
2024
Q3 		$2.05K Buy
+72
New +$1.83K ﹤0.01% 2173

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's CSTL Position: Q2 2026 in Review

Sterling Capital Management reduced its Castle Biosciences (CSTL) stake by 38% in Q2 2026, selling an estimated $8.2K and leaving 603 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

Sterling Capital Management first reported a position in CSTL in Q3 2024 and has held it in 8 quarters since. The position peaked at $63.7K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Sterling Capital Management held 603 shares of Castle Biosciences worth $14.4K as of Q2 2026.
  • Sterling Capital Management sold 368 Castle Biosciences shares in Q2 2026, an estimated $8.2K.
  • Castle Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2042 holding.
  • Sterling Capital Management first reported a position in Castle Biosciences in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Castle Biosciences position peaked at $63.7K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.